Illumina

Meet the MiSeq i100 Series – the new standard in sequencing simplicity with a 3-step setup, onboard DRAGEN analysis, and same-day results to accelerate genomic discovery and insights: https://bit.ly/4eTqugz

Thanks to our employees around the globe who participated in the Illumina Cares #StepsAgainstCancer campaign throughout October in support of organizations dedicated to fighting cancer. The campaign concluded this weekend with the Making Strides Against Cancer event in San Diego. We are honored to have been the presenting sponsor and have our CCO, Everett Cunningham, speak about our ongoing dedication to oncology innovation and research.    Learn more about how employees came together for this great cause: https://bit.ly/4e2Rzgx

Curious about what's new in the MiSeq i100 Series? Our Chief Technology Officer, Steven Barnard, deep dives on our latest sequencing innovation.

Why are countries racing to develop nationwide sequencing programs? The short answer: To address country-specific health needs. The Human Genome Project provided the first (almost) complete reference genome, but it didn’t say much about human variation. For that, scientists had to conduct massive population genomics (pop gen) studies, sequencing millions of people to better understand the genetic distinctions, in specific populations, that confer good health or disease. Learn about the emerging population genomics revolution and how it benefits us all: https://bit.ly/3UoxCtj

Our #DRAGEN methods paper in @Naturebiotechnology is finally out! Since the beginning of DRAGEN development, our mission has been to deliver, a comprehensive and accurate genome analysis to match and keep up with the advancement, quality and throughput of Illumina's #sequencing! This new paper in @Naturebiotechnology presents the methods, benchmarks and science behind the DRAGEN multi-genome mapping, the variant callers for SNV, SV, CNV, repeat expansions and the set of specialized callers that DRAGEN offers to genotype and discover variations in genes in medically relevant difficult to map regions. It also describes how DRAGEN scaled to support the UK Biobank and All of Us program, and is able to aggregate hundreds of thousands of gVCF incrementally to support cohort level research. Proud of the work of the DRAGEN team that always strives for excellence, and special thanks to Fritz Sedlazeck, Sairam Behera and the team at Baylor College of Medicine Human Genome Sequencing Center for the special collaboration. https://lnkd.in/gGUu9USC #bioInformatics

I’m excited to share exceptional progress in the field of newborn screening and Illumina’s role in accelerating the adoption of whole genome sequencing to provide earlier detection and improved outcomes for babies born with genetic disease.    Illumina is an active collaborator in Project GUARDIAN (Genomic Uniform-screening Against Rare Disease In All Newborns). GUARDIAN the largest study of its kind and investigates the utility of WGS to identify 255 early onset genetic conditions as compared to 65 conditions currently included in standard newborn screening. This collaboration, initiated in 2022 with Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, the New York State Department of Health, GeneDx and Sanofi, aims to offer expanded WGS-based screening to 100,000 babies from a diverse population.   While the study is ongoing, the promising initial findings were published today in JAMA, Journal of the American Medical Association. GUARDIAN is demonstrating the clear benefit of genomics as a powerful tool to help diagnose genetic disease earlier and treat faster when compared to standard screening and to do so at a time when access to care is more equitable – at birth.    GUARDIAN is a testament to the importance of our work at Illumina, the value we place on collaborating deeply with our customers and the impact we can collectively have on improving human health. #thisisthegenomeera

When it comes to enabling more genomic discoveries with NGS—the simpler, the better. That’s why our R&D teams designed benchtop sequencing systems for every lab, everywhere.

Tim Roloff Handschin, PhD and his team at the Institute of Medical Microbiology (IMM) at the University of Zurich were among the first to get their hands on the MiSeq i100 Series – what did they think? Read about their experience and the capabilities of the MiSeq i100 Series: https://bit.ly/3UlICYz

The MiSeq i100 Series is on tour! 🧬🌎 From San Diego to Shanghai, employees were excited to experience our latest sequencing technology at instrument meet and greet events. Next stop: even more scientific breakthroughs. #Genomics4All #IlluminaProud

I just launched the MiSeq i100 Series. As a seasoned product manager, I often reflect on the journey that follows a product launch. A few years of blood sweat and tears (sometimes literally!), driving a cross-functional team of brilliant minds through peaks of successes and valleys of failures until you feel confident enough to tell your leadership that you are ready for primetime. And then, the game is on! After a brief flash of limelight, you find yourself meticulously monitoring manufacturing processes, comparing orders against forecasts, evaluating pricing strategies, and planning for the next phase. Each piece of feedback—especially the critical ones—can feel personal, especially from people who think they know better… Being a product manager means caring deeply about every aspect of your product's lifecycle. The earlier you get involved in the development process, the more invested you become in its success. Being a product manager is also feeling the thrill of being in the eye of the storm, challenging yourself and your team daily and pushing the boundaries of your mind to learn from amazing colleagues and customers around you. Being a product manager is terrifyingly amazing! Illumina #productmanagement #productmanager #miseqi100